Handelsavisen
prelaunch
Companies Basic Materials ROSB.NS
RO
ROSB.NS NSE (India) Specialty Chemicals

Rosb.Ns

$506,65
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,10 %
Op margin
8,6 %
ROE
11,2 %
Net margin
6,2 %
Debt / equity
0,33
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

ROSB.NS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.

Business. ROSB.NS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.

Classification92 %
SectorBasic Materials
Business sectorChemicals
IndustrySpecialty Chemicals
ActivityChemicals
Generated · model-assisted
Sell-side consensus
BUY5 analysts
4 buy1 hold0 sell
Avg 12m price target601,75

Analyst recommendations

5 analysts · consensus Buy
Buy4
Hold1
Sell0
12-month price target
601,75
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
5 analysts · indicative
Ownership
not yet wired
Profitability
11,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ROSB.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ROSB.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ROSB.NS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.

    Classification92 %
    SectorBasic Materials
    Business sectorChemicals
    IndustrySpecialty Chemicals
    ActivityChemicals
    AI synthesis
    GENERATED

    ROSB.NS has a liquidity position that is characterized by a current ratio of 1.58, indicating that the company has sufficient current assets to cover its current liabilities. However, the company's free cash flow is negative at -391.03 million INR, and capital expenditures are substantial at -2.65 billion INR, suggesting a high reinvestment rate in its operations. The company's cash and equivalents amount to 922.14 million INR, which is less than its long-term debt of 4.36 billion INR, indicating a net cash outflow after accounting for total debt.

    In terms of profitability, ROSB.NS has a return on equity (ROE) of 11.19% and a return on assets (ROA) of 6.52%, which are key metrics for evaluating the efficiency of equity and asset utilization. The company's gross profit of 7.28 billion INR and operating income of 2.07 billion INR reflect its ability to generate profit from its core operations. The debt-to-equity ratio of 0.33 suggests a relatively conservative capital structure, with a lower proportion of debt compared to equity.

    ROSB.NS operates in a single business segment, and its revenue is primarily concentrated in one geographic region. The company's revenue of 23.96 billion INR is derived from the sale of chemical products, with no significant diversification across segments or regions. This concentration may expose the company to regional economic fluctuations and market-specific risks.

    The company's growth trajectory is influenced by its capital expenditures and operating cash flow. With a capital expenditure of -2.65 billion INR and an operating cash flow of 650.68 million INR, the company is investing heavily in its operations, which may support future growth. However, the negative free cash flow indicates that the company is not generating enough cash to cover its capital expenditures, which could impact its ability to sustain growth without external financing.

    ROSB.NS faces a medium liquidity risk, as indicated by its current ratio and negative free cash flow. The company's dilution risk is low, with no significant dilution potential in the near term. The company's risk assessment highlights the key flag of net cash being negative after subtracting total debt, which could affect its financial flexibility.

    Recent events and disclosures related to ROSB.NS include analyst estimates and price targets. The mean price target is 601.75 INR, with a median of 600.00 INR, and the high and low price targets are 637.00 INR and 570.00 INR, respectively. The mean recommendation from analysts is 1.80, indicating a generally positive outlook, with 2 strong-buy, 2 buy, and 1 hold ratings.

    Key takeaways
    • ROSB.NS has a conservative capital structure with a debt-to-equity ratio of 0.33.
    • The company's return on equity of 11.19% and return on assets of 6.52% indicate strong profitability.
    • ROSB.NS is heavily invested in capital expenditures, with a significant outflow of -2.65 billion INR.
    • The company's liquidity position is medium, with a current ratio of 1.58 but a negative free cash flow.
    • Analysts have a generally positive outlook on ROSB.NS, with a mean recommendation of 1.80 and a mean price target of 601.75 INR.
    • The company's revenue is concentrated in a single segment and geographic region, which may increase its exposure to market-specific risks.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $506,65
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $13.33B
    Net cash
    -$3.44B
    Current ratio
    1.6
    Debt / equity
    0.3
    ROA
    6.5%
    ROE
    11.2%
    Cash conversion
    44.0%
    CapEx / revenue
    -11.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    28,50
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    5
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate28,50
    Revenueno estimateno estimate26,6B INR
    Operating incomeno estimateno estimate2,4B INR
    Full-year consensus mean (period as reported by source) · consensus in INR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution5 analysts
    Strong buy2
    Buy2
    Hold1
    Sell0
    Strong sell0
    12-month price target$601,75 · Median $600,00
    Low $570,00High $637,00
    Operating income · consensus2,4B INR
    EPS surprise
    −5,5 %
    reported vs consensus · miss
    Revenue surprise
    −9,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$570,00
    Mean$601,75
    Median$600,00
    High$637,00
    Spot$506,65
    +18.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,6 %Above median
    Net Margin6,2 %Above median
    ROE11,2 %Above P75
    Capex / Rev-11,0 %Below median
    D/E0,33Below median
    Cash Conv0,44Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • ROSB.NS Market data — financials · 2026-05-29
    • Rossari Biotech Ltd Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ROSB.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage